St. Jude Medical CFO Sells $666,600 in Stock (STJ)
St. Jude Medical (NYSE:STJ) CFO Donald Zurbay sold 12,000 shares of the stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $55.55, for a total transaction of $666,600.00. Following the completion of the transaction, the chief financial officer now directly owns 9,731 shares in the company, valued at approximately $540,557. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of St. Jude Medical (NYSE:STJ) traded down 0.62% during mid-day trading on Monday, hitting $55.88. 2,306,582 shares of the company’s stock traded hands. St. Jude Medical has a 52-week low of $30.25 and a 52-week high of $57.17. The stock’s 50-day moving average is $52.74 and its 200-day moving average is $47.47. The company has a market cap of $16.048 billion and a price-to-earnings ratio of 26.56.
St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $0.96 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the company posted $0.86 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis.
A number of research firms have recently commented on STJ. Analysts at Barclays Capital raised their price target on shares of St. Jude Medical from $57.00 to $61.00 in a research note to investors on Monday, September 23rd. They now have an “overweight” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of St. Jude Medical in a research note to investors on Wednesday, September 18th. They now have a $57.00 price target on the stock. Finally, analysts at Wells Fargo & Co. upgraded shares of St. Jude Medical from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, August 9th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. St. Jude Medical presently has an average rating of “Hold” and a consensus target price of $47.85.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.